In this article, we will discuss Umbralisib (Dosage Overview). So, let’s get started.
Marginal Zone Lymphoma
Umbralisib is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
Umbralisib is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
The recommended dosage of Umbralisib is 800 mg taken orally once daily with food until disease progression or unacceptable toxicity.
Advise patients of the following:
• Swallow tablets whole. Do not crush, break, cut, or chew tablets.
• Take Umbralisib at the same time each day.
• If vomiting occurs, do not take an additional dose; continue with the next scheduled dose.
• If a dose is missed, take a missed dose unless it is less than 12 hours until the next scheduled dose.
Provide prophylaxis for Pneumocystis jirovecii pneumonia (PJP) during treatment with
Umbralisib. Consider prophylactic antivirals during treatment with Umbralisib to prevent cytomegalovirus (CMV) infection, including CMV reactivation.